Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Oct 20 - Oct 25
However, based on mechanistic understanding and data from similar medications, theres no evidence of permanent metabolic impairment
Drowsiness and fatigue Many people feel tired or drowsy after injection, likely related to MT-2's effects on the nervous system
Mild sleep apnea is different from moderate-to-severe OSA
Based on typical regulatory timelines: Phase 3 completion: Late 2026 FDA submission: Late 2026 to early 2027 Earliest possible FDA approval: Mid-to-late 2027 US commercial launch: Early 2028 (projected) If the rollout of semaglutide and tirzepatide taught us anything, it's that demand for these medications consistently outpaces supply in the first year or two
US$ 22.85
US$ 27.02
US$ 21.44
US$ 28.73
US$ 28.06
%20(1).png)
US$ 29.48
